{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T06:12:19Z","timestamp":1779257539276,"version":"3.51.4"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:p>Over the past four decades, the HIV epidemic in sub-Saharan Africa has shifted from an acute, high-mortality phase to an era of widespread antiretroviral therapy (ART), driven by global scale up and the introduction of potent regimens such as dolutegravir-based combinations. While viral suppression is now increasingly achievable, the central challenge has evolved toward maintaining durable virological control across the life course. We argue that program success can no longer be defined by the mere attainment of suppression, but by the sustained maintenance of undetectable viral load and preservation of drug effectiveness at the population level. From a virological perspective, incomplete suppression, including persistent low-level viremia, creates predictable conditions for resistance selection over time, even with high\u2013genetic barrier agents. In settings where CD4 monitoring is infrequent, gradual immune deterioration may go unnoticed despite apparently acceptable viral load thresholds. Emerging integrase inhibitor resistance should therefore be interpreted as a systems-level warning signal rather than an isolated clinical event. We discuss dolutegravir as an extraordinary yet finite therapeutic resource, the risks of functional monotherapy when nucleoside backbones are compromised, and the role of postfailure strategies, including protease inhibitor\u2013anchored regimens, within optimized care pathways. Central to this approach is recognizing diagnostics\u2014viral load monitoring, CD4 assessment, and targeted genotypic resistance testing\u2014as essential clinical infrastructure. Sustaining ART gains in Africa requires moving from \u201cminimum for all\u201d toward differentiated, high-quality lifelong care integrated within broader public health platforms.<\/jats:p>","DOI":"10.3389\/fpubh.2026.1819844","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T05:48:28Z","timestamp":1779256108000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Maintain, not obtain: rethinking HIV care in sub-Saharan Africa in the era of dolutegravir"],"prefix":"10.3389","volume":"14","author":[{"given":"Carlo Federico","family":"Perno","sequence":"first","affiliation":[{"name":"Bambino Gesu Pediatric Hospital IRCCS","place":["Rome, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Orlando","sequence":"additional","affiliation":[{"name":"Department of Biomedicine and Prevention, University of Rome Tor Vergata","place":["Rome, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noorjehan Abdul","family":"Majid","sequence":"additional","affiliation":[{"name":"DREAM Program, Community of Sant\u2019Egidio","place":["Maputo, Mozambique"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hawa","family":"Sangare","sequence":"additional","affiliation":[{"name":"DREAM Program, Community of Sant\u2019Egidio","place":["Blantyre, Malawi"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Luanga","sequence":"additional","affiliation":[{"name":"DREAM Program, Community of Sant\u2019Egidio","place":["Blantyre, Malawi"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Roccucci","sequence":"additional","affiliation":[{"name":"Department of Biomedicine and Prevention, University of Rome Tor Vergata","place":["Rome, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loredana Andreea","family":"Silaghi","sequence":"additional","affiliation":[{"name":"Department of Biomedicine and Prevention, University of Rome Tor Vergata","place":["Rome, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zita","family":"Sidumo","sequence":"additional","affiliation":[{"name":"DREAM Program, Community of Sant\u2019Egidio","place":["Maputo, Mozambique"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide","family":"Brambilla","sequence":"additional","affiliation":[{"name":"DREAM Program, Community of Sant\u2019Egidio","place":["Rome, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanna","family":"Ceffa","sequence":"additional","affiliation":[{"name":"DREAM Program, Community of Sant\u2019Egidio","place":["Rome, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Guidotti","sequence":"additional","affiliation":[{"name":"ASL Rome 1","place":["Rome, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fausto","family":"Ciccacci","sequence":"additional","affiliation":[{"name":"Department of Biomedicine and Prevention, University of Rome Tor Vergata","place":["Rome, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1665666","DOI":"10.3389\/fpubh.2025.1665666","article-title":"The global response to HIV\/AIDS in Sub-Saharan Africa: achievements, challenges, and perspectives for the future","volume":"13","author":"Orlando","year":"2025","journal-title":"Front Public Health"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1097\/qad.0000000000004007432","article-title":"Transition to dolutegravir-based art in 35 low- and middle-income countries: a global survey of HIV care clinics","volume":"38","author":"Zaniewski","year":"2024","journal-title":"AIDS (London, England)"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"e284","DOI":"10.1016\/s2352-3018(23)00047-4340","article-title":"Implementation and outcomes of dolutegravir-based first-line antiretroviral therapy for people with HIV in South Africa: a retrospective cohort study","volume":"10","author":"Dorward","year":"2023","journal-title":"The Lancet HIV"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s12981-025-00810-z","article-title":"Dolutegravir rollout for treatment of HIV with a focus on advanced disease and tuberculosis coinfection: findings from rural Kwazulu-Natal, South Africa (2019\u20132023)","volume":"22","author":"Moyo","year":"2025","journal-title":"AIDS Res Ther"},{"key":"ref5","volume-title":"World AIDS Day Report 2025: Overcoming Disruption: Transforming the AIDS Response","year":"2025"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"e284","DOI":"10.1093\/cid\/ciag161","article-title":"Patterns of HIV-1 viral load suppression and drug resistance during the dolutegravir transition: a population-based longitudinal study","author":"Martin","year":"2026","journal-title":"Clin Infect Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-026-13013-2","article-title":"Efficacy of dolutegravir-based therapy in achieving virological suppression in PLHIV in low-and middle-income countries: real-world evidence from a large clinical cohort in Cameroon","volume":"26","author":"Tadenfok","year":"2026","journal-title":"BMC Infect Dis"},{"key":"ref8","year":"2025"},{"key":"ref9","volume-title":"Eeacs-guidelinesVersion 13.0","year":"2025"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1001\/jama.2024.24543","article-title":"Antiretroviral drugs for treatment and prevention of HIV in adults: 2024 recommendations of the international antiviral society\u2013USA panel","volume":"333","author":"Gandhi","year":"2025","journal-title":"JAMA"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.antiviral.2013.12.007","article-title":"Evolution of HIV treatment guidelines in high- and low-income countries: converging recommendations","volume":"103","author":"Richardson","year":"2014","journal-title":"Antivir Res"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12981-024-00626-3","article-title":"Changing how the third 95 is counted: suitable indicators for measuring u=u with findings from Taiwan","volume":"21","author":"Huang","year":"2024","journal-title":"AIDS Res Ther"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"e11345","DOI":"10.1371\/journal.pone.0011345","article-title":"Dynamics of HIV-1 quasispecies during antiviral treatment dissected using ultra-deep pyrosequencing","volume":"5","author":"Hedskog","year":"2010","journal-title":"PLoS One"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12040915","article-title":"The\u02d8 phenomenon of antiretroviral drug resistance in the context of human immunodeficiency virus treatment: dynamic and ever evolving subject matter","volume":"12","author":"Apetroaei","year":"2024","journal-title":"Biomedicine"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"59","DOI":"10.56557\/jodagh\/2025\/v18i19168","article-title":"Drug resistance in anti-viral medications: a case study of human immunodeficiency virus","volume":"18","author":"Akinsola","year":"2025","journal-title":"J Dis Glob Health"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"102166","DOI":"10.1016\/j.eclinm.2023.102166","article-title":"Retrospective longitudinal analysis of low-level viremia among HIV-1 infected adults on antiretroviral therapy in Kenya","volume":"63","author":"Aoko","year":"2023","journal-title":"EClinicalMedicine"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2024.2447613","article-title":"The prevalence of low-level viraemia and its association with virological failure in people living with HIV: a systematic review and meta-analysis","volume":"14","author":"Zhao","year":"2024","journal-title":"Emerg Microbes Infect"},{"key":"ref18","volume-title":"Consolidated Guidelines on HIV Prevention, Testing, Treatment, Service Delivery and Monitoring: Recommendations for a public Health Approach","year":"2021"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"e0330792","DOI":"10.1371\/journal.pone.0330792","article-title":"The dolutegravir failure cohort: a multi-country longitudinal cohort with a randomised clinical trial of continued dolutegravir versus switch to darunavir in people with viraemia while on dolutegravir in sub-Saharan Africa (the ndovu study) protocol","volume":"21","author":"Ombajo","year":"2026","journal-title":"PLoS One"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1186\/s12879-025-11395-3","article-title":"Low-level viremia and subsequent virologic failure among people living with HIV: a retrospective cohort study in China","volume":"25","author":"Tan","year":"2025","journal-title":"BMC Infect Dis"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"e1815","DOI":"10.1016\/s2214-109x(22)00413-2","article-title":"Low-level viraemia among people living with HIV in Nigeria: a retrospective longitudinal cohort study","volume":"10","author":"Chun","year":"2022","journal-title":"Lancet Glob Health"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1080\/21505594.2021.2004743","article-title":"Persistent low-level viremia in persons living with HIV undertreatment: an unresolved status","volume":"12","author":"Crespo-Bermejo","year":"2021","journal-title":"Virulence"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1093\/cid\/ciac762","article-title":"Virologic failure following low-level viremia and viral blips during antiretroviral therapy: results from a European multicenter cohort","volume":"76","author":"Elvstam","year":"2022","journal-title":"Clin Infect Dis"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1097\/QAD.0000000000004138","article-title":"Drug resistance testing at regimen failure in individuals diagnosed with HIV-1 between 2010 and 2018 in Israel","volume":"39","author":"Wagner","year":"2025","journal-title":"AIDS"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12879-023-08906-5","article-title":"Incidence of low-level viremia and its impact on virologic failure among people living with HIV who started an integrase strand transfer inhibitors: a longitudinal cohort study","volume":"24","author":"Lao","year":"2024","journal-title":"BMC Infect Dis"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/S1473-3099(19)30036-2","article-title":"Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial","volume":"19","author":"Aboud","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"e381","DOI":"10.1016\/S2352-3018(22)00092-3","article-title":"Dolutegravir or darunavir\/ritonavir in second-line treatment after first-line failure (NADIA): 96-week outcomes","volume":"9","author":"Paton","year":"2022","journal-title":"The Lancet HIV"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"e677","DOI":"10.1016\/S2352-3018(20)30238-1","article-title":"Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 noninferiority trial in Cameroon","volume":"7","author":"Calmy","year":"2020","journal-title":"The Lancet HIV"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"e592\u2013e593","DOI":"10.1016\/S2352-3018(25)00127-4","article-title":"Predictors of treatment-emergent resistance to dolutegravir","volume":"12","author":"McCluskey","year":"2025","journal-title":"Lancet HIV"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"ofae321","DOI":"10.1093\/ofid\/","article-title":"Dolutegravir resistance in african programmatic settings among patients with failure of dolutegravir-based ART","volume":"11","author":"Murphy","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"ref31","volume-title":"WHO Updated Recommendations on HIV Clinical Management: Recommendations for a public Health Approach","year":"2025"},{"key":"ref32","volume-title":"HIV Drug Resistance: Brief Report 2024","year":"2024"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1093\/jac\/dkae087","article-title":"Prevalence of pretreatment HIV resistance to integrase inhibitors in West African and southeast Asian countries","volume":"79","author":"Aghokeng","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1093\/cid\/ciae185","article-title":"Emergence of acquired dolutegravir resistance in treatment-experienced people with HIV in Lesotho","volume":"79","author":"Tschumi","year":"2024","journal-title":"Clin Infect Dis"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"399","DOI":"10.3390\/v16030399","article-title":"Prevalence of emergent dolutegravir resistance mutations in people living with HIV: a rapid scoping review","volume":"16","author":"Chu","year":"2024","journal-title":"Viruses"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1080\/14787210.2025.2529431","article-title":"How frequent is dolutegravir resistance?","volume":"23","author":"van Osch","year":"2025","journal-title":"Expert Rev Anti-Infect Ther"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"e698","DOI":"10.1016\/S2214-109X(24)00553-9","article-title":"Predicted dolutegravir resistance in people living with HIV in South Africa during 2020\u201335: a modelling study","volume":"13","author":"Loosli","year":"2025","journal-title":"Lancet Glob Health"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1186\/s12879-025-11639-2","article-title":"HIV dolutegravir resistance and multiclass failure in Mozambique: findings from a real-world cohort","volume":"25","author":"Ciccacci","year":"2025","journal-title":"BMC Infect Dis"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12981-025-00708-w","article-title":"Brief communication: virological outcomes and dolutegravir resistance mutations in HIV-infected patients: a multicenter retrospective cohort study in Mozambique","volume":"22","author":"Doro Altan","year":"2025","journal-title":"AIDS Res Ther"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1007\/s11904-022-00616-y","article-title":"Long-acting injectable cabotegravir for HIV prevention: what do we know and need to know about the risks and consequences of cabotegravir resistance?","volume":"19","author":"Parikh","year":"2022","journal-title":"Curr HIV\/AIDS Rep"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.3390\/v15081732","article-title":"Current ARTs, virologic failure, and implications for AIDS management: a systematic review","volume":"15","author":"Foka","year":"2023","journal-title":"Viruses"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"e627","DOI":"10.1016\/S2352-3018(25)00164-X","article-title":"The clinical and economic impact of genotypic resistance testing for people diagnosed with persistent virological non-suppression on tenofovir-lamivudine-dolutegravir in South Africa: a modelling study","volume":"12","author":"Hyle","year":"2025","journal-title":"The Lancet HIV"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1038\/s41591-023-02763-0","article-title":"HIV drug resistance to integrase inhibitors in low-and middle-income countries","volume":"30","author":"Fokam","year":"2024","journal-title":"Nat Med"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"e25501","DOI":"10.1002\/jia2.25501","article-title":"Drug level testing as a strategy to determine eligibility for drug resistance testing after failure of ART: a retrospective analysis of south african adult patients on second-line ART","volume":"23","author":"Hermans","year":"2020","journal-title":"J Int AIDS Soc"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1097\/QAD.0000000000003520","article-title":"Point-of-care urine tenofovir testing to predict HIV drug resistance among individuals with virologic failure","volume":"37","author":"McCluskey","year":"2023","journal-title":"AIDS"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"e332","DOI":"10.1016\/S2352-3018(23)00051-6","article-title":"Long-acting antiretrovirals and HIV treatment adherence","volume":"10","author":"Nachega","year":"2023","journal-title":"The Lancet HIV"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/S1473-3099(24)00289-5","article-title":"Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial","volume":"24","author":"Kityo","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1056\/nejmoa2115542","article-title":"Capsid inhibition with lenacapavir in multidrug-resistant HIV-1 infection","volume":"386","author":"Segal-Maurer","year":"2022","journal-title":"N Engl J Med"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"7781","DOI":"10.1097\/ms9.0000000000003775","article-title":"Breaking barriers in HIV management: the rise of long-acting lenacapavir","volume":"87","author":"Chandani","year":"2025","journal-title":"Ann Med Surg"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1097\/coh.0000000000000732","article-title":"Implementation of long-acting antiretroviral therapy in low-income and middle-income countries","volume":"17","author":"Cresswell","year":"2022","journal-title":"Curr Opin HIV AIDS"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.3390\/v14122591","article-title":"Different pathways conferring integrase strand-transfer inhibitors resistance","volume":"14","author":"Richetta","year":"2022","journal-title":"Viruses"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"1667417","DOI":"10.3389\/fpubh.2025.1667417","article-title":"The warning bell of dolutegravir resistance: rethinking HIV service models in Africa","volume":"13","author":"Ciccacci","year":"2025","journal-title":"Front Public Health"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"1674241","DOI":"10.3389\/fpubh.2025.1674241","article-title":"The DREAM programme, lessons learnt from 20 years of experience","volume":"13","author":"Doro Altan","year":"2025","journal-title":"Front Public Health"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1819844\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T05:48:30Z","timestamp":1779256110000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1819844\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":53,"alternative-id":["10.3389\/fpubh.2026.1819844"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2026.1819844","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]},"article-number":"1819844"}}